Jazz Pharmaceuticals plc Long-Term Debt, Maturity, Remainder of Fiscal Year
Jazz Pharmaceuticals plc (JAZZ) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $15.50 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2026-08-03
- 2026-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $15.50M.
- 2026-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $1.02B.
- 2025-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $7.75M.
- 2025-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $15.50M.
| Period end | Long-Term Debt, Maturity, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $15.50M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $1.02B 10-Q · filed 2026-05-05 |
| 2025-09-30 | $7.75M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $15.50M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $23.25M 10-Q · filed 2025-05-07 |
| 2024-09-30 | $7.75M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $590.50M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $598.25M 10-Q · filed 2024-05-02 |
| 2023-09-30 | $7.75M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $15.50M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $23.25M 10-Q · filed 2023-05-10 |
| 2022-09-30 | $7.75M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $15.50M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $23.25M 10-Q · filed 2022-05-04 |
| 2021-09-30 | $7.75M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $234.31M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $243.85M 10-Q · filed 2021-05-04 |
| 2020-09-30 | $8.35M 10-Q · filed 2020-11-02 |
| 2020-06-30 | $16.69M 10-Q · filed 2020-08-04 |
| 2020-03-31 | $25.04M 10-Q · filed 2020-05-05 |
| 2019-09-30 | $8.35M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $16.69M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $25.04M 10-Q · filed 2019-05-07 |
| 2018-09-30 | $8.35M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $16.69M 10-Q · filed 2018-08-07 |
| 2017-09-30 | $9.02M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $18.05M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $27.07M 10-Q · filed 2017-05-09 |
| 2016-09-30 | $9.02M 10-Q · filed 2016-11-08 |
| 2016-06-30 | $18.75M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $28.19M 10-Q · filed 2016-05-10 |
| 2015-09-30 | $9.40M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $9.68M 10-Q · filed 2015-08-05 |
| 2015-03-31 | $7.11M 10-Q · filed 2015-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |